Hideaki Bando, Shogo Kumagai, Daisuke Kotani, Saori Mishima, Takuma Irie, Kota Itahashi, Yosuke Tanaka, Takumi Habu, Sayuri Fukaya, Masaki Kondo, et al. Atezolizumab following definitive chemoradiotherapy in patients with unresectable locally advanced esophageal squamous cell carcinoma - a multicenter phase 2 trial (EPOC1802). Nature cancer. 2025
Shin Kobayashi, Yoshiaki Nakamura, Tadayoshi Hashimoto, Hideaki Bando, Eiji Oki, Takahiro Karasaki, Hidehito Horinouchi, Yukinori Ozaki, Hiroji Iwata, Taigo Kato, et al. Japan society of clinical oncology position paper on appropriate clinical use of molecular residual disease (MRD) testing. International journal of clinical oncology. 2025
Hideaki Bando, Yoichi Naito, Tomoyuki Yamada, Takao Fujisawa, Mitsuho Imai, Yasutoshi Sakamoto, Yusuke Saigusa, Kouji Yamamoto, Yutaka Tomioka, Nobuyoshi Takeshita, et al. A prospective study comparing highly qualified Molecular Tumor Boards with AI-powered software as a medical device. International journal of clinical oncology. 2025. 30. 2. 172-179
John H Strickler, Tanios Bekaii-Saab, Andrea Cercek, Volker Heinemann, Yoshiaki Nakamura, Kanwal Raghav, Salvatore Siena, Josep Tabernero, Eric Van Cutsem, Takayuki Yoshino, et al. MOUNTAINEER-03 phase III study design: first-line mFOLFOX6 + tucatinib + trastuzumab for HER2+ metastatic colorectal cancer. Future oncology (London, England). 2025. 21. 3. 303-311
Mitsuho Imai, Yoshiaki Nakamura, Takayuki Yoshino. Transforming cancer screening: the potential of multi-cancer early detection (MCED) technologies. International journal of clinical oncology. 2025. 30. 2. 180-193
